Phibro Animal Health (PAHC) Cash & Equivalents (2013 - 2026)

Phibro Animal Health's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $54.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 8.99% year-over-year to $54.9 million; the TTM figure through Mar 2026 stood at $54.9 million (down 8.99% YoY), while the FY2025 annual figure was $68.0 million, down 3.65% from the prior year.
• Cash & Equivalents was $54.9 million for Q1 2026 at Phibro Animal Health, down from $55.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $76.3 million in Q3 2022 to a low of $33.0 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $58.6 million across 5 years, with a median of $60.4 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 51.81% in 2023, then surged 103.44% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $68.4 million in 2022, then slumped by 51.81% to $33.0 million in 2023, then soared by 103.44% to $67.1 million in 2024, then decreased by 17.28% to $55.5 million in 2025, then retreated by 1.0% to $54.9 million in 2026.
• The last three Cash & Equivalents figures came in at $54.9 million (Q1 2026), $55.5 million (Q4 2025), and $72.8 million (Q3 2025), per Business Quant data.